• Although prostaglandins were discovered four decades ago, definition of their remarkable range of biological activity was delayed until the past decade when Bergstrom et al. (1) identified the structures of the major prostaglandins and set the foundation for their synthesis. What has happened thereafter is only too familiar: a full-scale invasion by prostaglandins into disciplines as disparate as demography and neurophysiology has resulted in a rapid accumulation of information, much of which appears contradictory and resists meaningful classification. For example, prostaglandins of the E series can either attenuate or augment the vasoconstrictor response to nerve stimulation, although augmentation occurs only at high doses (2) . PGE 2 , the major renal prostaglandin, can modulate the renal response to antidiuretic hormone (ADH) by inhibiting stimulation of adenyl cyclase by ADH, although a prostaglandin of the E series can itself activate adenyl cyclase (3) . Therefore, when considering biological activities, the prostaglandin in question must be unequivocally identified among the more than 14 naturally occurring prostaglandins and its dose and route of administration must be noted, since major differences in the effects of a prostaglandin depend on these factors in a way that appears to be unique for biological systems even in comparison with steroids.
CHEMISTRY, BIOSYNTHESIS, AND METABOLISM
The prostaglandins are 20-carbon unsaturated fatty acids containing a five-membered ring. The particular biological properties of a prostaglandin depend primarily on the substituents of the ring. In the 9-position, a ketone group characterizes prostaglandins of the E series and a hydroxyl group characterizes those of the F series ( Fig. 1) . Prostaglandins of the A series differ from those of the E series by the absence of a hydroxyl group in the 11-position and the presence of a double bond in the ring. The subscript numeral indicates the degree of unsaturation of the side chains, e.g., PGE 2 has two double bonds in its side chains and PGEj has one. Prostaglandins having similar degrees of unsaturation possess common precursors: arachidonic acid is the precursor for PGE 2 and PGF 2a and dihomo-y-linolenic acid is the precursor for PGE, and PGFia. PGE compounds readily undergo dehydration within the ring resulting in the formation of PGA compounds. Because of the instability of the former, it is difficult to be certain that prostaglandins of the A series occur naturally (4) , except in human seminal vesicular fluid (5) . Lee et al. (6) isolated three prostaglandins from the rabbit renal medulla: PGE 2 , PGF 2 «, and PGA 2 . However they thought that PGA 2 was a possible artifact produced from PGE 2 during extraction of the prostaglandins. Concurrently, Daniels et al. (7) identified PGE 2 as the principal renal prostaglandin. Within a series of prostaglandins, quantitative differences in their biological activities occur, whereas qualitative differences are exceptional. Qualitative differences between prostaglandins of the F series and those of the E and the A series are encountered frequently. The latter two groups of prostaglandins resemble each other in their biological actions. However, PGE compounds are more potent than PGA compounds, and, unlike the PGA compounds, they, as well as the PGF compounds, are almost entirely removed from the blood on passage across the lung (8) . PGE 2 has a renal vasodilator potency fivefold that of PGA 2 (9) . In contrast, PGF.a does not affect renal blood flow under the same conditions. The renal vasodilator actions of prostaglandins of the E and the A series have not been dissociated from concurrent natriuresis (8) is vital to the proposal that endogenous prostaglandins modulate autonomic nervous activity generally (10) and renal pressor systems specifically (11) . Prostaglandins of the E series are more potent in this regard than are those of the A series (2) . In contrast, PGF 2 « augments vasoconstriction produced by pressor stimuli in some vascular beds (2), although the renal bed is exempted from this action (9) . The prostaglandin concentrations reported in tissues are more an indication of biosynthetic activity than of endogenous prostaglandin content. In the rabbit renal medulla, concentrations of PGE 2 as high as 17 fig/g (12) have been reported; this concentration approaches that in human seminal vesicular fluid where the highest concentrations are found (13) . However, if the kidney is quick-frozen, concentrations of PGE 2 are only 0.005 /xg/g. The interstitial cells of. the renal medulla are considered to be the site of synthesis and storage of renal prostaglandins. Moreover, changes in ultrastructure and granularity of interstitial cells have been related to hypertension and altered renal function (14) . Although interstitial cells can synthesize prostaglandins, this function may not be invested exclusively in this type of cell within the kidney in view of the lesser biosynthetic capacity (15) of these cells compared with that of slices of renal medulla (16) and the identification by a histochemical method of the cells of the collecting ducts as the site of the most active prostaglandin synthesis (17) . The studies of Anggard et al. (12) also suggest that renal prostaglandins do not accumulate in any subcellular particle, indicating that they are not stored. Release of prostaglandins by the kidney in response to a stimulus such as infusion of angiotensin II, then, denotes increased prostaglandin synthesis which results in the immediate entry of the prostaglandin into the extracellular compartment. After their release within the renal medulla, prostaglandins are not degraded appreciably locally because of the virtual exclusion of metabolizing enzymes from this zone. The absence of the major metabolizing enzyme, 15-hydroxy prostaglandin dehydrogenase, from the inner medulla (18) where synthesizing enzymes have been shown to be most active has intriguing implications concerning duration and sites of activity of prostaglandins after their release intrarenally. The question of prostaglandin synthesis by the renal cortex, which could have large functional implications, is complicated by the presence of very active metabolizing enzymes in the cortex. Although only trace quantities of PGE 2 and PGF 2a have been detected in rabbit renal cortex (19) , prostaglandin synthesis in this zone, although low, may be sig-' nificant. The recent report by Larsson and Anggard (20) of prostaglandin synthesis by the rabbit renal cortex equal to less than 10% of that of the medulla involved the use of a microsomal fraction which excluded metabolizing enzymes. Crowshaw (personal communication), using a purified acetone powder preparation of rabbit renal cortex, has confirmed these observations. Furthermore, it is unlikely that the release within the cortex of newly synthesized prostaglandins has major extracellular effects beyond a sharply circumscribed area due to their rapid and efficient metabolism to 15-keto derivatives (20) . This situation contrasts sharply with the much larger quantities of PGE 2 and PGF 2a synthesized and released within the renal medulla, as discussed above.
The initial step in the synthesis of prostaglandins presumably is activation of an acyl hydrolase, such as phospholipase A, which releases from a phospholipid an unsaturated fatty acid, e.g., arachidonic acid, the precursor of PGE 2 and PGF 2 « (21). The precursor is rapidly converted to prostaglandins E and F after undergoing oxidative cyclization. One of the intermediates in the synthesis of prostaglandins, a cyclic endoperoxide, may possess independent biological activity. Gryglewski and Vane (22) have suggested that a series of vasoactive substances results from activation of acyl hydrolases of which prostaglandins are the end products. A by-product, the lysophospholipid, resulting from phospholipaseinduced release of prostaglandin precursors from phospholipids possesses potent biological actions (23) . A lysophospholipid has been proposed to be a naturally occurring inhibitor of renin (24) . Those factors operating in vivo which determine whether the synthesis of PGE 2 or PGF 2 a will predominate have not been identified, although selective formation of PGE 2 occurs intrarenally in response to those vasoactive hormones which have been examined thus far (25) .
PRQSTAGLANDINS: LOCAL HORMONES OR CIRCULATING HORMONES?
To appreciate the sphere of activity of prostaglandins, it is useful to assign them to that class of endogenous substances called local or tissue hormones. A local hormone may be synthesized or activated in many organs or tissues; however, the activity of a local hormone is usually restricted to the site of its formation, the venous system, and those cardiopulmonary structures proximal to its degradation in the lung. PGE 2 and PGF 2a , although stable in blood, are almost completely inactivated on passage across the lung (26) . The other prostaglandin isolated from the kidney, PGA 2 , could function as a circulating hormone, since prostaglandins of the A series escape destruction in the lung (8) . However, PGA 2 must originate from conversion of PGE 2 , since the breakdown of the biosynthetic intermediate, the cyclic endoperoxide, results in PGE 2 and PGF 2a , not PGA 2 (27) . Crowshaw (28) , using rabbit and dog renal medullary preparations, has consistently failed to demonstrate biosynthesis of PGA 2 after addition of either labeled arachidonic acid or PGE 2 . These findings support those of Hamberg (4), who also has been unable to show formation of PGA 2 in rabbit renal medulla under conditions which promote synthesis of PGE 2 and PGF 2a . Davis and Horton (29) have reported relatively high concentrations of PGE 2 and PGF 2a in renal venous blood of the rabbit, but a PGA-Iike substance was not recovered from renal venous blood in sufficient quantity, in contrast to PGE-and PGF-like material, to permit its definitive identification. If one assumes that the PGA-like material was PGA, although it could have been a PGB or a PGC compound ( Fig. 1 ), then its concentration was considerably less than one-tenth of that of PGE 2 . Since the renal vasodilator-diuretic activity of PGA 2 is one-fifth of that of PGE 2 (9), differences in their concentrations in renal venous blood expressed in terms of equivalency of their vasodilator-diuretic actions exceed fiftyfold. We conclude that PGA 2 , if present in the kidney, is present in amounts which are not readily detected and that this problematic renal production of PGA 2 could not account for the
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high peripheral blood levels reported for PGA compounds in man (30, 31) . Nonetheless, the proposal that a prostaglandin of the A series is a circulating hormone (32) should be considered an open issue in view of two recent studies. In the first, Jones and Cammoek (33) have demonstrated in plasma the enzymatic conversion of PGAj and PGA 2 to isomers designated PGCi and PGC 2 , respectively, which are more potent than their PGA precursors and share with them the ability to escape pulmonary degradation ( Fig. 1 ). However, the activity of this isomerase in many species including man is low or absent. In the second study, a substance (s), which is immunoreactive with antibodies to PGA compounds, has been described in peripheral plasma of normal adults (30) at concentrations, about 1.5 ng/ml, severalfold greater than those of prostaglandins of the E series (31) . Inasmuch as information on the identification, fate, and biological activity of prostaglandin precursors and metabolites is incomplete, experience dictates caution when considering the possibility of circulating prostaglandins. This consideration has particular pertinence to the claims of specificity for measurements of prostaglandins by radioimmunoassay, since one or more metabolites of the parent compound or related substances may cross-react with the antibody to the prostaglandin being measured. There are sufficient precedents in the convoluted story concerning the development of a radioimmunoassay for angiotensin II (34) to make one wary of radioimmunoassay procedures in the early phases of their development. We interpret the evidence presently available to support primary local actions for renal prostaglandins. Bradykinin is also a local hormone which shares with prostaglandins potent vasoactive properties and an uncertain intrarenal status. Bradykinin-prostaglandin interactions have recently been described within the kidney (25); these interactions may herald identification of another intrarenal regulatory system in addition to the adrenergic nervous-renin-angiotensin system.
Although arterial concentrations of prostaglandins of the E and the F series are probably less than 0.02 ng/ml under resting conditions (35) , precipitous increases in the arterial levels of prostaglandins can occur, e.g., in response to pulmonary embolism (36) . In addition, in advanced lung disease, particularly when it is associated with extensive shunting of blood, arterial levels of prostaglandins can approach venous levels. The localization of the major prostaglandin-metabolizing enzymes in the cortex of the kidney (18) would diminish considerably the threat to body fluid homeostasis presented by sudden increases in the arterial levels of prostaglandins.
Since prostaglandins possess diverse actions and affect most biological systems, construction of their intrarenal actions based on their intravascular administration demands recognition that blood levels rarely, if ever, exceed 10 10 moles/ml (< 35 ng/ml). Concentrations of this magnitude would be expected only in the venous effluent from organs having large biosynthetic capacity, representing peak levels which are not maintained. Arterial levels which are less than one-fiftieth those occurring in renal venous blood probably rarely exceed 20 pg/ml blood (35) . When blood levels of administered prostaglandins are excessive, a sought-for direct renal action may be superseded or obscured by their systemic effects. Questionable purposes are served by studies of the effects of administration of prostaglandins by bolus injection or in amounts which establish blood levels in excess of 100 ng/ml. Furthermore, no route of administration of prostaglandins reproduces the effects evoked by release of endogenous prostaglandins from an organ in terms of either concentrations achieved at their sites of action, vascular elements initially affected, or the sequence of vascular elements affected. These considerations are frequently overlooked when tentative physiological roles are inferred on the basis of the reported effects of exogenous prostaglandins on renal function. For example, since administration of a PGA compound reduces renal medullary blood flow and increases cortical blood flow, it has been reasoned that a deficiency of prostaglandins intrarenally will result in cortical ischemia (32) . On the contrary, release of prostaglandins within the renal medulla where metabolizing enzymes are deficient or absent (20) should primarily increase medullary blood flow. Furthermore, the presence of the major prostaglandin-metabolizing enzymes in the cortex should assure a primary medullary action of renal prostaglandins (20) . Thus, deficiency of renal prostaglandins induced by inhibition of prostaglandin synthetase should result primarily in ischemia of the renal medulla, not the renal cortex. Studies directed towards examination of the physiological roles of renal prostaglandins are scarce because of (1) the considerable difficulties involved in measuring levels of prostaglandins in biological fluids and (2) the absence of agents which block effector responses efficiently and predictably. However, the important discovery that anti-inflammatory acids such as salicylates and indomethacin inhibit synthesis of prostaglandins (37) has already resulted in several findings of major importance, namely, PGE-. is vital to the maintenance of resting blood flow to the kidney (35) and acts as a determinant of the intrarenal distribution of blood flow (38) .
PGEs MODULATES PRESSOR SYSTEMS
The studies of Hedqvist (10) are an excellent introduction to the role of prostaglandins as intrarenal modulators of vasoconstrictor-antidiuretic systems. These studies suggest a negative feedback mechanism whereby a PGE compound is released on nerve stimulation in addition to the neruotransmitter; the prostaglandin then inhibits further release of the neurotransmitter. Hedqvist (10) has shown that stimulation of the adrenergic nerves supplying the heart and the spleen releases a PGE compound and norepinephrine simultaneously from these organs. A primary prejunctional action of PGE compounds seems likely, since (1) the release of norepinephrine is increased after inhibition of prostaglandin synthesis and (2) exogenous PGE 2 inhibits the response to nerve stimulation more readily than it does that to injected norepinephrine. Increasing the concentration of calcium reverses prostaglandin inhibition of the neuroeffecttor response to adrenergic stimulation (39) . Involvement of prostaglandins at this fundamental level, translocation of ionic calcium (40) and facilitation of its binding (41) , may explain the nonspecific nature of prostaglandin modulation of pressor hormones. Thus, PGE 2 inhibits not only adrenergicinduced renal vasoconstriction, but also vasoconstriction effected by angiotensin II (9) . Since vasoconstrictor responses to angiotensin II (42) and adrenergic nerve stimulation (43) are calcium dependent, the demonstration that a prostaglandin of the E series affects binding of calcium ions appears vital to its activity as a modulator. Because ionic calcium may be required for expression of the activity of hormones and appears to be involved in the initial hormone-receptor interaction (44), the importance of a substance which affects disposition of calcium ions cannot be overestimated. Changes in cellular binding of ionic calcium produced by prostaglandins may be pivotal in prostaglandin-adenyl cyclase interactions.
PROSTAGLANDINS AND THE ANTIHYPERTENSIVE FUNCTION OF THE KIDNEY
The antihypertensive function of the kidney may depend on the secretion of an antipressor sub-Circulation Research. Vol. XXXlll, November 1973 PROSTAGLANDINS AND THE KIDNEY 483 stance(s) by the kidney in response to elevated blood pressure rather than the regulation by the kidney of extracellular fluid volume. The continuous secretion of this substance(s) is thought to be responsible for maintaining blood pressure at normal levels (45) , since bilateral nephrectomy results in hypertension which is not necessarily dependent on changes in extracellular fluid volume.
Demonstration that a prostaglandin opposes constriction of renal blood vessels produced by pressor hormones is a necessary first step in relating renal prostaglandins to the antihypertensive function of the kidney. Norepinephrine shares with angiotensin II (46) the ability to release a PGE-like substance from the kidney, associated with blunting of the renal vasoconstrictor-antidiuretic action of the pressor hormone (47) . When this substance is not released during infusion of the pressor hormone, renal blood flow and urine flow do not recover. In addition, stimulation of the renal nerves so as to effect moderate reductions in renal blood flow does not release a PGE compound from the kidney, and blood flow and urine flow remain depressed. Release of renal prostaglandins is not, then, obligatory in response to nerve stimulation, suggesting that their release is dependent on a critical change in either renal function or the extracellular concentration of a substance resulting from nerve stimulation. However, under other conditions, such as increased renal perfusion pressure, stimulation of the renal nerves releases prostaglandins from the kidney (48) . An important additional finding, which will be expanded later to establish a relationship between the capacity of the kidney to release PGE 2 and the state of sodium balance, is that the increases in the concentration of the PGE-like substance encompass a fiftyfold range (47) . Although the PGE-like substance is indistinguishable from a PGE compound by physicochemical, chromatographic, and pharmacological criteria, the amounts released preclude definitive identification (46, 47) . However, two recent studies have strengthened the tentative identification of PGEo as the mediator of these effects. In the first study, inhibition of prostaglandin synthesis has been shown to enhance the renal vasoconstrictor action of angiotensin II and norepinephrine associated with failure of the pressor hormones to release prostaglandins intrarenally (49) . In the second study, PGE 2 has been shown to inhibit the vasoconstrictor and antidiuretic actions of angiotensin II and norepinephrine when it is infused into the renal artery at rates which establish concentrations, about 0.5 ng PGE 2 /ml Circulation Research, Vol. XXX11I, November 1975 blood, comparable to those of a PGE-like substance reported in venous effluent of the kidney during escape from the renal effects of pressor hormones (9) .
The mechanism operating through prostaglandins which modulates the renal actions of pressor hormones may also account for the natriuresis produced by increased renal perfusion pressure (50) . The capacity of the kidney to increase synthesis of prostaglandins in response to increased renal perfusion pressure is deduced from comparison of two recent studies. In the first, in which renal blood flow was allowed to vary during nerve stimulation, reductions in renal blood flow v/ere not associated with release of prostaglandins from the kidney (47) . In contrast, in the second study, renal blood flow was kept constant and renal perfusion pressure was allowed to vary. Under these conditions, nerve stimulation which greatly increased renal perfusion pressure was associated with an increased efflux of prostaglandins from the kidney (48) . Thus, increased renal perfusion pressure appears to be a sufficient condition for release of renal prostaglandins.
Unilateral renal ischemia has also been shown to be associated with increased concentrations of prostaglandins in the venous blood of both ischemic and contralateral kidneys, acutely in dogs (51), as well as in hypertensive subjects (52) . Angiotensin II presumably mediates the release of prostaglandins from the contralateral kidney, since infusion of angiotensin II in anesthetized dogs, at a rate which establishes concentrations in blood within the range of those reported in renovascular hypertension, < 0.5 ng/ml blood (53) , releases a PGE compound into renal venous blood (46) . Although prostaglandin-angiotensin interactions may affect the development of renovascular hypertension, other antihypertensive lipids of renal origin may prove decisive in aborting those events which culminate in hypertension, namely an antihypertensive neutral lipid (54) and a renin inhibitor (24) . Either or both of these substances may operate in concert with renal prostaglandins in preventing hypertension. The work of Muirhead et al. (54) in particular compels consideration of a circulating antihypertensive substance originating from the renal medulla and challenges invocation of a mechanism having a primary locus of action intrarenally (55) such as would be required for investing the renal antihypertensive function in PGEo. The question of PGA 2 of renal origin functioning as an antihypertensive substance has been dealt with previously and answered in the negative.
PROSTAGLANDINS AND REACTIVITY OF RENAL BLOOD VESSELS TO PRESSOR HORMONES
Interactions of pressor hormones and prostaglandins which are sodium dependent may be major determinants of vascular reactivity. Contrary to the generally accepted relationship that an increased concentration of sodium enhances vascular reactivity (56), Kilcoyne and Cannon (57) have found that sodium restriction potentiates the renal vasoconstrictor response to norepinephrine. This observation is not unexpected, if it is recognized that the regional vasoconstrictor response to a pressor stimulus is affected by the capacity of the stimulus to release a PGE compound from the vascular territory. The amount of PGE 2 released from the kidney by pressor hormones may be related to the state of sodium balance or some function of it such as extracellular fluid volume or renal medullary tonicity. Plasma renin activity has been used as an index of the state of sodium balance (58) . The norepinephrine-induced increase in concentration of a PGE compound in renal venous blood, which ranges from 0.5 to 24.2 ng/ml, is unrelated to the dose of the amine but is inversely related to plasma renin activity (59) . Thus, norepinephrine releases the largest amount of a PGE compound when plasma renin activity is low (positive sodium balance) and the least when plasma renin activity is high (negative sodium balance). A similar relationship to sodium balance may exist for the vasoconstrictor action of angiotensin II (60). However, Hollenberg et al. (61) , having confirmed in man the observations of Kilcoyne and Cannon (57) concerning vascular responsiveness to norepinephrine as affected by sodium balance, have shown that the renal vasoconstrictor response to angiotensin II, unlike the response to norepinephrine, is potentiated by positive sodium balance. These findings emphasize the need, in future studies on vascular reactivity, to define the capacity of the pressor stimulus to release prostaglandins, since the latter will, in large part, determine the degree of residual vasoconstriction. Since increased vascular reactivity has been reported to precede the onset of hypertension (62) , these studies suggest that deficiency of prostaglandin production may initiate hypertension. Hypertension, then, may be considered to result from uncompensated deficiencies or excesses of one or more components of the vasodepressor and vasopressor systems, respectively.
MAINTENANCE OF RENAL BLOOD FLOW AND DETERMINANTS OF ITS DISTRIBUTION
The evidence presented thus far suggests that renal prostaglandins do play a role in defending renal function against excesses of vasoconstrictorantidiuretic hormones. However, a basal efflux of prostaglandins from the kidney persists in the absence of any challenge to the renal circulation (25) . Inhibition of prostaglandin synthesis by either indomethacin or meclofenamate results in decreased renal blood flow closely correlated with a decline in renal efflux of a PGE compound, in spite of increased renal perfusion pressure (35) . Changes in renal efflux of a PGF compound are unrelated to reductions in renal blood flow. Femoral blood flow and cardiac output are not affected. The interpretation that PGE 2 contributes to resting renal blood flow is strengthened by demonstrating identical effects of indomethacin on the isolated canine kidney, thereby excluding the operation of extrarenal factors. Thus, renal vascular tone at rest, heretofore considered to be determined by "autonomous, intrinsic activity of the renal arterioles" (63), depends, in large part, on continued production of a renal prostaglandin. However, the mean reduction of 45% in renal blood flow produced by inhibition of prostaglandin synthesis (35) cannot be accounted for in terms of changes in blood flow to the renal medulla or to that zone, the juxtamedullary cortex, from which the medullary blood vessels take origin. In considering these results, it is important to recognize that the vascular architecture of the canine kidney might partially determine the magnitude of these changes, since nephrons having long loops predominate in the dog, in contrast to man in whom they constitute less than 20% of the nephrons (64) . Furthermore, renal prostaglandins may affect cortical structures via tubular fluid, since PGEi> and PGFoa, considered to originate intrarenally, have been identified in the urine (65) . In addition, a cortical site of action for renal prostaglandins seems probable in view of the important findings of Herbaczynska-Cedro and Vane (66) that renal autoregulation is dependent on the activity of prostaglandin synthetase. In this study, reduction of renal perfusion pressure resulted in release of prostaglandinlike material into renal venous effluent coincident with compensatory renal vasodilation. Indomethacin abolished simultaneously the release of prostaglandinlike material by the kidney and the renal autoregulatory response to decreased renal perfusion pressure. Since inhibition of prostaglandin synthesis by anti-inflammatory drugs affects all products of prostaglandin synthetase, as well as other enzymes (67), it is important to confirm any study which depends on this action of antiinflammatory agents by alternate methods, e.g., prostaglandin antagonists of high specificity which are presently unavailable. Thus, the availability of agents which effectively block cellular responses to endogenous prostaglandins in vivo is indispensable for the fullest definition of the nature and the range of prostaglandin-effector mechanisms and would yield information analogous to that obtained from aand /J-receptor blockade of adrenergic neuroeffector responses. A similar relationship between basal production of prostaglandins and resting blood flow may be anticipated wherever transporting epithelia of large capacity are present, such as the gut and lung. In addition, functional and reactive hyperemia of the kidney, gut, and exocrine tissue may depend on their capacity to increase synthesis of a PGE compound in response to either metabolic or vasoactive hormonal signals (68).
The sector of activity of renal prostaglandins has been tentatively identified by measuring the distribution of blood flow to the inner and the outer cortex with radioactive microspheres before and after inhibition of prostaglandin synthesis in the isolated canine kidney (38) . This technique allows estimation of changes in medullary blood flow, since blood vessels of the renal medulla are derived primarily from the efferent arterioles of the inner cortex. Thus, changes in inner cortical blood flow reflect changes in medullary blood flow. Inasmuch as prostaglandin synthetase is located in the renal medulla and the major degradative enzyme, the 15hydroxy prostaglandin dehydrogenase, is located primarily in the renal cortex (20) , the actions of renal prostaglandins in the medulla will be relatively unopposed (Fig. 2 ). The consequences of increased medullary vascular resistance resulting from inhibition of synthesis of PGE 2 , if the medulla is the primary site of action of PGE 2 , will be reduction in blood flow to the inner cortex. This proposal has been validated: after indomethacin administration, blood flow and its fractional distribution to the inner cortex are invariably decreased and the decreases correlate with the reduction in concentration in blood of a PGE compound. In contrast, outer cortical blood flow does not decrease, and fractional distribution to this zone increases. However, these results in the isolated canine kidney may partially depend on the relatively high blood levels of PGE compound in this preparation; namely, greater than tenfold those of the in Nephrons having long and short loops of Henle are shown on the left. The origin of the renomedullary blood vessels (vasa recta) from the efferent arterioles of the juxtameduUary glomeruli is schematized on the right {after Fourman, J., and Moffat, D. B.: Blood Vessels of the Kidney. Oxford, Blackwell Scientific Publications, 1971) . The primary effect of inhibition of prostaglandin synthesis is indicated by a decrease in the diameter of the vasa recta as schematized in the vascular cross sections. The prostaglandin-metabolizing and the prostaglandin-synthesizing enzymes are segregated, the former to the cortex and the latter to the medulla. situ kidney, thereby facilitating any demonstration of the effects of an intervention dependent on elimination of endogenous prostaglandins. In addition, these observations cannot be extrapolated to other mammals because of the aforementioned species differences in the vascular architecture of the kidneys. These objections notwithstanding, the study supports the proposal that PGE 2 functions in the renal medulla as a local hormone which participates in the regulation of medullary and, thereby, deep cortical blood flow with all the attendant effects on renal function. In this regard, the renin-angiotensin system has been shown to participate in the regulation of blood flow to the same zone, the inner cortex, affected by PGE 2 but in a reciprocal fashion (69). Thus, the antagonism of PGE 2 and angiotensin intrarenally is reaffirmed.
RENAL PGF?«: A DETERMINANT OF CARDIAC PERFORMANCE?
PGF 2a , the second most abundant renal prostaglandin, neither amplifies neurogenic renal vasoconstriction (9) nor affects renal vascular resistance in concentrations as high as 40 ng/ml blood (25) . In contrast, changes in the concentration of PGE 2 in arterial blood of 0.1 ng/ml produce renal vasodilation and diuresis (8) . The determinants of PGF 2 « synthesis intrarenally remain undefined, since both pressor and depressor hormones result in a selective release in PGE 2 . The systemic pressor action of PGF2a may be primarily related to increased cardiac output consequent to enhanced venomotor tone (70). In this regard, Hinman (71) first suggested in 1967 that PGF 2 « may fulfill a coupling role between renal function and cardiac performance, i.e., PGFoo may be released in response to depressed renal function to increase cardiac output. A substance affecting venous return and synthesized intrarenally may account for the earliest hemodynamic changes in experimental hypertension, i.e., increased cardiac output preceding heightened arteriolar tone (72).
